Table 5.

Number of Anti-VEGF Injections Administered for Age-related Macular Degeneration

Year of Initial Treatment	Number of Anti-VEGF Injections within the Specified Period
		Accumulative							By the Year
		0–12 mos	0–24 mos	0–36 mos	0–48 mos	0–60 mos	0–72 mos	0–84 mos	0–12 mos	13–24 mos	25–36 mos
2011	Mean ± SD	3.46 ± 1.88	4.65 ± 3.41	5.82 ± 4.96	6.97 ± 6.55	8.18 ± 8.26	9.42 ± 10.03	10.75 ± 11.90	3.46 ± 1.88	1.20 ± 2.04	1.15 ± 2.07
	Median (quantile)	3 (2–4)	3 (3–6)	4 (3–8)	4 (3–9)	5 (3–11)	5 (3–13)	6 (3–14)	3 (2–4)	0 (0–2)	0 (0–2)
2012	Mean ± SD	3.73 ± 2.16	5.09 ± 3.84	6.34 ± 5.53	7.57 ± 7.22	8.86 ± 9.00	10.26 ± 10.91	-	3.73 ± 2.16	1.36 ± 2.16	1.24 ± 2.20
	Median (quantile)	3 (2–5)	4 (3–7)	4 (3–9)	5 (3–10)	5 (3–12)	6 (3–14)	-	3 (2–5)	0 (0–2)	0 (0–2)
2013	Mean ± SD	3.73 ± 2.21	5.09 ± 3.89	6.33 ± 5.57	7.53 ± 7.27	8.87 ± 9.11	-	-	3.73 ± 2.21	1.36 ± 2.15	1.21 ± 2.15
	Median (quantile)	3 (2–5)	4 (3–7)	4 (3–9)	5 (3–10)	5 (3–12)	-	-	3 (2–5)	0 (0–2)	0 (0–2)
2014	Mean ± SD	3.60 ± 2.32	5.00 ± 4.08	6.24 ± 5.82	7.51 ± 7.60	-	-	-	3.60 ± 2.32	1.38 ± 2.20	1.21 ± 2.17
	Median (quantile)	3 (2–5)	4 (2–7)	4 (2–9)	5 (2–10)	-	-	-	3 (2–5)	0 (0–2)	0 (0–2)
2015	Mean ± SD	3.61 ± 2.34	5.05 ± 4.17	6.41 ± 6.03	-	-	-	-	3.61 ± 2.34	1.42 ± 2.24	1.29 ± 2.28
	Median (quantile)	3 (2–5)	4 (2–7)	4 (2–9)	-	-	-	-	3 (2–5)	0 (0–2)	0 (0–2)
2016	Mean ± SD	3.68 ± 2.41	5.22 ± 4.31	-	-	-	-	-	3.68 ± 2.41	1.50 ± 2.32	-
	Median (quantile)	3 (2–5)	4 (2-7)	-	-	-	-	-	3 (2–5)	0 (0–3)	-
2017	Mean ± SD	3.77 ± 2.46	-	-	-	-	-	-	3.77 ± 2.46	-	-
	Median (quantile)	3 (2–5)	-	-	-	-	-	-	3 (2–5)	-	-
Average		3.66 ± 2.30	5.05 ± 4.03	6.27 ± 5.69	7.44 ± 7.27	8.69 ± 8.88	9.90 ± 10.55	10.75 ± 11.90	3.66 ± 2.30	1.39 ± 2.20	1.23 ± 2.19

SD = standard deviation; VEGF = vascular endothelial growth factor.